节点文献

美常安联合柳氮磺吡啶治疗溃疡性结肠炎的疗效及对血清TNF-α、IL-6、IL-8水平的影响

Ulcerative Colitis: Efficacy of Meichangan plus Sulfasalazine and Its Influence on Serum TNF-α, IL-6, IL-8

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 李杨麟喻晓东苏林唐运东秦漓漓王芬利

【Author】 LI Yang-lin;YU Xiao-dong;SU Lin;TANG Yun-dong;QIN Li-li;WANG Fen-li;Department of Gastroenterology Medicine,Guilin Second People’s Hospital;

【机构】 桂林市第二人民医院消化内科

【摘要】 目的:探索美常安联合柳氮磺吡啶治疗溃疡性结肠炎(UC)的疗效,及对血清TNF-α、IL-6、IL-8水平的影响。方法:选择自2012年9月至2014年12月我院收治的100例UC患者,按照随机数表法分成对照组和观察组,每组50例。对照组患者口服给予柳氮磺吡啶,观察组患者口服给予美常安联合柳氮磺吡啶治疗。统计分析两组患者的临床有效率、症状改善、不良反应发生情况及治疗前后患者血清中TNF-α、IL-6、IL-8水平的变化。结果:观察组中总有效率为92.00%显著高于对照组中总有效率为48.00%(P<0.05);两组患者治疗后的主要临床症状较治疗前均有明显改善(P<0.05),且观察组患者治疗后主要症状缓解率明显高于对照组(P<0.05);两组患者治疗后血清中TNF-α、IL-6、IL-8水平均显著低于治疗前,且观察组明显低于对照组(P<0.05);两组患者不良反应发生率之间的差异无统计学意义(P>0.05)。结论:美常安联合柳氮磺吡啶治疗UC具有良好的临床疗效,能显著改善患者的临床症状和患者血清中炎症因子的水平,值得在临床上推广使用。

【Abstract】 Objective: To explore the efficacy of Meichangan combined with sulfasalazine in treatment of ulcerative colitis(UC)and its influence on the serum TNF-α, IL-6, IL-8. Methods: A total of 100 patients with UC, who were treated in Guilin Second People’s Hospital from September 2012 to December 2014, were randomly divided into control group(n=50) and observation group(n=50). The control group was treated with sulfasalazine, while the observation group was treated with Meichangan combined with sulfasalazine. The clinical efficacy, clinical symptoms improvement, incidence of adverse reactions, and the changes of serum TNF-α, IL-6, IL-8 level before and after treatment in the two groups were statistically analyzed. Results: The total effective rate(92.00%) in the observation group was significantly higher than that(48.00%) in the control group(P<0.05); The main clinical symptoms of two groups after treatment were significantly improved than before treatment(P<0.05), meanwhile the main symptom remission rate after treatment in observation group was obviously higher than that in control group(P<0.05). The serum TNF-α, IL-6, IL-8 levels in the two groups after treatment were significantly lower than before treatment, the above indexes in observation group were significantly lower than those in control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion:Meichangan plus sulfasalazine has a good clinical effect in the treatment of patients with UC, and it can significantly improve the clinical symptoms and reduce the serum TNF-α, IL-6, IL-8 levels, which is worth of clinical application.

  • 【文献出处】 现代生物医学进展 ,Progress in Modern Biomedicine , 编辑部邮箱 ,2016年10期
  • 【分类号】R574.62
  • 【被引频次】26
  • 【下载频次】67
节点文献中: 

本文链接的文献网络图示:

本文的引文网络